Part 5/15:
De Grey's organization, the "SENS Research Foundation," concentrates on the toughest damage types—those that haven’t yet been effectively targeted—because other groups are already making strides on more straightforward issues. He highlights that the field is rapidly moving from theoretical science to practical, scalable therapies, driven increasingly by private sector investment and entrepreneurship.